Low-dose rituximab in autoimmune hemolytic anemia: 10 years after
2019
TO THE EDITOR:
Rituximab is becoming the preferred second-line choice for steroid-refractory warm autoimmune hemolytic anemia (wAIHA) and the first-line choice for cold agglutinin disease (CAD). However, rituximab is an expensive treatment that is not available worldwide; it is also not in
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
9
Citations
NaN
KQI